Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12247426 | 0.81 | HTT (0.58) | HTTMAPK1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL19398928 | 0.81 | HTT (0.40) | HTTSMN1; SMN2 | |
| SCHEMBL17603718 | 0.81 | HTT (0.40) | HTTALDH1A1SMN1; SMN2MLYCDGAA | |
| SCHEMBL31374213 | 0.76 | SMN1; SMN2 (0.36) | MAPK1ALDH1A1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL21879877 | 0.73 | HTT (0.47) | HTTMAPK1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL21879981 | 0.72 | RAB9A (0.46) | HTTMAPK1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL17868539 | 0.70 | SMN1; SMN2 (0.48) | HTTMAPK1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL17603693 | 0.69 | PDE9A (0.40) | — | |
| SCHEMBL17604139 | 0.69 | L3MBTL1 (0.38) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL31374181 | 0.68 | HTT (0.35) | HTTMAPK1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024726-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE | KINNATE BIOPHARMA INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20170273985-A1 | TRICYCLIC DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-20170273985-A1 | TRICYCLIC DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| WO-2016042775-A1 | TRICYCLIC DERIVATIVE | SUNOVION PHARMACEUTICALS INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2016042775-A1 | TRICYCLIC DERIVATIVE | SUNOVION PHARMACEUTICALS INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273985-A1 | TRICYCLIC DERIVATIVE | PDE3A, PDE2A, PDE5A | HTT 4546/4885MAPK1 2891/4885ALDH1A1 497/4885 |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | PDE3A, PDE5A, PDE2A | HTT 4382/4885MAPK1 2843/4885ALDH1A1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.